Literature DB >> 6133545

Reduced clearance of triazolam in old age: relation to antipyrine oxidizing capacity.

D J Greenblatt, M Divoll, D R Abernethy, L J Moschitto, R B Smith, R I Shader.   

Abstract

Thirty-three healthy male and female volunteers aged 21 to 87 years received a single 0.5 mg oral dose of triazolam. Plasma triazolam concentrations were measured in multiple samples drawn during 24 h after the dose. Mean triazolam elimination half-life was not significantly different between young and elderly men (3.0 vs 4.6 h), nor between young and elderly women (2.7 vs 3.2 h). However, apparent oral clearance of triazolam was significantly reduced in elderly as compared to young groups of both sexes, leading to higher peak plasma concentrations and increased total area under the curve. Values of half-life and clearance of antipyrine, a low-extraction hepatically oxidized compound, were poorly correlated with those of triazolam (r = 0.34 and 0.44, respectively), suggesting different mechanisms controlling age-related changes in clearance of these two hepatically oxidized drugs.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6133545      PMCID: PMC1427766          DOI: 10.1111/j.1365-2125.1983.tb01503.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  27 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Antipyrine metabolism in man: influence of age, alcohol, caffeine, and smoking.

Authors:  R E Vestal; A H Norris; J D Tobin; B H Cohen; N W Shock; R Andres
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

3.  Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans.

Authors:  D J Greenblatt; R I Shader; K Franke; D S MacLaughlin; J S Harmatz; M D Allen; A Werner; E Woo
Journal:  J Pharm Sci       Date:  1979-01       Impact factor: 3.534

Review 4.  Factors influencing antipyrine elimination.

Authors:  I H Stevenson
Journal:  Br J Clin Pharmacol       Date:  1977-06       Impact factor: 4.335

Review 5.  Drug therapy: drug disposition in old age.

Authors:  D J Greenblatt; E M Sellers; R I Shader
Journal:  N Engl J Med       Date:  1982-05-06       Impact factor: 91.245

6.  Spectrophotometric assay of antipyrine in plasma: a reevaluation.

Authors:  D J Greenblatt; A Locniskar
Journal:  Int J Clin Pharmacol Biopharm       Date:  1979-09

7.  Absorption of oral and intramuscular chlordiazepoxide.

Authors:  D J Greenblatt; R I Shader; S M MacLeod; E M Sellers; K Franke; H G Giles
Journal:  Eur J Clin Pharmacol       Date:  1978-06-19       Impact factor: 2.953

8.  Phenazone (antipyrine) metabolism and distribution in young and elderly adults.

Authors:  D E Liddell; F M Williams; R H Briant
Journal:  Clin Exp Pharmacol Physiol       Date:  1975 Nov-Dec       Impact factor: 2.557

9.  Lorazepam kinetics in the elderly.

Authors:  D J Greenblatt; M D Allen; A Locniskar; J S Harmatz; R I Shader
Journal:  Clin Pharmacol Ther       Date:  1979-07       Impact factor: 6.875

10.  Effect of aging and cigarette smoking on antipyrine and indocyanine green elimination.

Authors:  A J Wood; R E Vestal; G R Wilkinson; R A Branch; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1979-07       Impact factor: 6.875

View more
  25 in total

Review 1.  Age-related changes in protein binding of drugs: implications for therapy.

Authors:  M K Grandison; F D Boudinot
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

Review 2.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (Part II).

Authors:  D J Greenblatt; J S Harmatz; R I Shader
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

4.  The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis.

Authors:  D G Le Couteur; A J McLean
Journal:  Clin Pharmacokinet       Date:  1998-05       Impact factor: 6.447

5.  Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage.

Authors:  R J Flanagan; A Johnston; A S White; P Crome
Journal:  Br J Clin Pharmacol       Date:  1989-10       Impact factor: 4.335

Review 6.  Clinical pharmacokinetics of non-opiate abused drugs.

Authors:  U Busto; R Bendayan; E M Sellers
Journal:  Clin Pharmacokinet       Date:  1989-01       Impact factor: 6.447

7.  Excessive motor impairment two hours after triazolam in the elderly.

Authors:  H U Fisch; G Baktir; G Karlaganis; C Minder; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

8.  Premedication with sublingual triazolam compared with oral diazepam.

Authors:  V K Kontinen; E L Maunuksela; J Sarvela
Journal:  Can J Anaesth       Date:  1993-09       Impact factor: 5.063

9.  Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of benzodiazepines. II. Triazolam.

Authors:  S K Gupta; E H Ellinwood; A M Nikaido; D G Heatherly
Journal:  Pharm Res       Date:  1990-06       Impact factor: 4.200

Review 10.  Benzodiazepine poisoning. Clinical and pharmacological considerations and treatment.

Authors:  P Gaudreault; J Guay; R L Thivierge; I Verdy
Journal:  Drug Saf       Date:  1991 Jul-Aug       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.